Cargando…

The use of stem cells in ischemic heart disease treatment

Ischemic heart disease is a major cause of death and disabilities worldwide. Unfortunately, not all patients are suitable for direct revascularization. Cell-based therapies may be alternative options because of their potential to promote neovascularisation and endothelial repair, improving myocardia...

Descripción completa

Detalles Bibliográficos
Autores principales: Litwinowicz, Radoslaw, Kapelak, Bogusław, Sadowski, Jerzy, Kędziora, Anna, Bartus, Krzysztof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180025/
https://www.ncbi.nlm.nih.gov/pubmed/30310400
http://dx.doi.org/10.5114/kitp.2018.78446
_version_ 1783362115834216448
author Litwinowicz, Radoslaw
Kapelak, Bogusław
Sadowski, Jerzy
Kędziora, Anna
Bartus, Krzysztof
author_facet Litwinowicz, Radoslaw
Kapelak, Bogusław
Sadowski, Jerzy
Kędziora, Anna
Bartus, Krzysztof
author_sort Litwinowicz, Radoslaw
collection PubMed
description Ischemic heart disease is a major cause of death and disabilities worldwide. Unfortunately, not all patients are suitable for direct revascularization. Cell-based therapies may be alternative options because of their potential to promote neovascularisation and endothelial repair, improving myocardial perfusion. The success of cell-based therapies depends on the type of implanted stem cells, delivery method and underlying disease. Several different cell populations including bone marrow-derived mononuclear cells (MNCs), mesenchymal stromal cells (MSCs), CD34+, CD133+, endothelial progenitor cells, adipose-derived mesenchymal stromal cells (ASCs) and stem cells from placenta and umbilical cord have been investigated. Presently, no consensus exists about the best cell type for clinical regenerative therapy. Because the system of coronary arteries in the ischemic area is poor and most of the coronary artery is significantly narrowed or closed, direct implantation of stem cells in the ischemic area of the heart muscle appears an attractive method.
format Online
Article
Text
id pubmed-6180025
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-61800252018-10-11 The use of stem cells in ischemic heart disease treatment Litwinowicz, Radoslaw Kapelak, Bogusław Sadowski, Jerzy Kędziora, Anna Bartus, Krzysztof Kardiochir Torakochirurgia Pol Review Paper Ischemic heart disease is a major cause of death and disabilities worldwide. Unfortunately, not all patients are suitable for direct revascularization. Cell-based therapies may be alternative options because of their potential to promote neovascularisation and endothelial repair, improving myocardial perfusion. The success of cell-based therapies depends on the type of implanted stem cells, delivery method and underlying disease. Several different cell populations including bone marrow-derived mononuclear cells (MNCs), mesenchymal stromal cells (MSCs), CD34+, CD133+, endothelial progenitor cells, adipose-derived mesenchymal stromal cells (ASCs) and stem cells from placenta and umbilical cord have been investigated. Presently, no consensus exists about the best cell type for clinical regenerative therapy. Because the system of coronary arteries in the ischemic area is poor and most of the coronary artery is significantly narrowed or closed, direct implantation of stem cells in the ischemic area of the heart muscle appears an attractive method. Termedia Publishing House 2018-09-24 2018-09 /pmc/articles/PMC6180025/ /pubmed/30310400 http://dx.doi.org/10.5114/kitp.2018.78446 Text en Copyright: © 2018 Polish Society of Cardiothoracic Surgeons (Polskie Towarzystwo KardioTorakochirurgów) and the editors of the Polish Journal of Cardio-Thoracic Surgery (Kardiochirurgia i Torakochirurgia Polska) http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Review Paper
Litwinowicz, Radoslaw
Kapelak, Bogusław
Sadowski, Jerzy
Kędziora, Anna
Bartus, Krzysztof
The use of stem cells in ischemic heart disease treatment
title The use of stem cells in ischemic heart disease treatment
title_full The use of stem cells in ischemic heart disease treatment
title_fullStr The use of stem cells in ischemic heart disease treatment
title_full_unstemmed The use of stem cells in ischemic heart disease treatment
title_short The use of stem cells in ischemic heart disease treatment
title_sort use of stem cells in ischemic heart disease treatment
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180025/
https://www.ncbi.nlm.nih.gov/pubmed/30310400
http://dx.doi.org/10.5114/kitp.2018.78446
work_keys_str_mv AT litwinowiczradoslaw theuseofstemcellsinischemicheartdiseasetreatment
AT kapelakbogusław theuseofstemcellsinischemicheartdiseasetreatment
AT sadowskijerzy theuseofstemcellsinischemicheartdiseasetreatment
AT kedzioraanna theuseofstemcellsinischemicheartdiseasetreatment
AT bartuskrzysztof theuseofstemcellsinischemicheartdiseasetreatment
AT litwinowiczradoslaw useofstemcellsinischemicheartdiseasetreatment
AT kapelakbogusław useofstemcellsinischemicheartdiseasetreatment
AT sadowskijerzy useofstemcellsinischemicheartdiseasetreatment
AT kedzioraanna useofstemcellsinischemicheartdiseasetreatment
AT bartuskrzysztof useofstemcellsinischemicheartdiseasetreatment